{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:17:39Z","timestamp":1787926659211,"version":"build-2784847793"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T-lineage acute leukemias are aggressive malignancies for which treatment options are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the efficacy and safety of a non-cytotoxic regimen combining venetoclax, azacitidine, and dexamethasone (VAD) as first-line induction therapy for T-cell acute lymphoblastic leukemia (T-ALL) and T\/myeloid mixed-phenotype acute leukemia (T-Myeloid MPAL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical parameters and survival data of 11 patients with newly-diagnosed T-ALL or T-Myeloid MPAL who received the VAD regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The complete remission (CR) rate and adverse events were assessed. Kaplan\u2013Meier curves were constructed to evaluate survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 11 patients (7 with early T-cell precursor [ETP] ALL, 2 with T-Myeloid MPAL, and 2 with non-ETP T-ALL), the overall CR rate after one cycle of VAD therapy was 90.9%, with 45.5% achieving measurable residual disease (MRD) negativity by flow cytometry. The historically poor-prognosis ETP-ALL subgroup showed an 85.7% CR rate (6\/7), while both T-Myeloid MPAL cases attained MRD negativity. No tumor lysis syndrome or treatment-related mortality occurred. Over a median follow-up of 358 days, all 5 patients who received transplantations remained relapse-free.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The VAD regimen demonstrated a high response rate and favorable safety, enabling effective transplantation bridging with avoidance of conventional cytotoxic therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261480378","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:51:56Z","timestamp":1787694716000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3206-907X","authenticated-orcid":false,"given":"Yutian","family":"Lei","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Duan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourong","family":"Miao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Qiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixuan","family":"Qian","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-4027","authenticated-orcid":false,"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2003.11.003"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-045351"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05544.x"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1522442"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24947"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574566"},{"key":"e_1_3_9_10_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology-Acute Lymphoblastic Leukemia (Version 1.2022). Accessed April 4 2022.https:\/\/www.nccn.org\/"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577654"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.219"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16154"},{"issue":"5","key":"e_1_3_9_19_2","first-page":"528","article-title":"Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab","volume":"11","author":"Punatar S","year":"2021","unstructured":"Punatar S, Gokarn A, Nayak L, et al. Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab. Am J Blood Res 2021; 11(5): 528\u2013533.","journal-title":"Am J Blood Res"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1941938"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2344998"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1957876"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000379"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.10.002"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.608"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002672"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i26.6200"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02414-4"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-465138"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10725"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0353"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01968-8"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06597-3"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284228"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04354-2"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05162-0"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0436-0"},{"key":"e_1_3_9_40_2","first-page":"8811673","article-title":"Venetoclax and Decitabine for T\/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)","volume":"2020","author":"Klocke H","year":"2020","unstructured":"Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and Decitabine for T\/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS). Case Rep Hematol 2020; 2020: 8811673. https:\/\/doi.org\/10.1155\/2020\/8811673","journal-title":"Case Rep Hematol"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071776"},{"issue":"3","key":"e_1_3_9_42_2","first-page":"193","article-title":"Acquired hypofibrinogenemia in patients with leukemia during steroid therapy","volume":"62","author":"Ogasawara F","year":"2021","unstructured":"Ogasawara F, Ito T, Nakamura M, et al. Acquired hypofibrinogenemia in patients with leukemia during steroid therapy. Rinsho Ketsueki 2021; 62(3): 193\u2013195. https:\/\/doi.org\/10.11406\/rinketsu.62.193","journal-title":"Rinsho Ketsueki"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13738"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261480378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261480378","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261480378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:18:13Z","timestamp":1787923093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261480378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["10.1177\/20406207261480378"],"URL":"https:\/\/doi.org\/10.1177\/20406207261480378","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20406207261480378"}}